SOURCES SOUGHT
68 -- Synthesis of Non-Isotopically Labeled Aerotoxic Syndrome Adducted Reference Peptides
- Notice Date
- 5/30/2012
- Notice Type
- Sources Sought
- NAICS
- 325998
— All Other Miscellaneous Chemical Product and Preparation Manufacturing
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 2012-43696
- Archive Date
- 6/16/2012
- Point of Contact
- Tayaria L Smith, Phone: 7704882797
- E-Mail Address
-
gqq4@cdc.gov
(gqq4@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- Notice of Intent Ref# 2012-43696 The Centers for Disease Control and Prevention, National Center for Environmental Health, Division of Agency for Toxic Substances and Disease Registry, Procurement and Grants Office intents to award a sole source, firm fixed price contract, in accordance with FAR Part 13 and FAR Part 6.302(1), using simplified acquisition procedures, to TNO Locatie Rijswijk, Lange Kleiweg 137, Rijswijk ZH, 2288 GJ, The Netherlands, for a period of 12 months. The contractor will synthesize o-cresyl phosphate ester-adducted and phosphate ester adducted non-isotopically labeled (native) nonapeptides to serve as standard reference materials for the full characterization of the method in preparation for future transfer of the method to state laboratories. Performance Work Statement Title of Project: Synthesis of Non-Isotopically Labeled Aerotoxic Syndrome Adducted Reference Peptides C.1 Background and Need - An isotope dilution mass spectrometry method has been developed for measuring exposure to organophosphorus engine lubricants in humans using serum. This method requires peptide calibration standards and internal standards for accurate quantitation. In order to transfer this method to state laboratories in the Laboratory Response Network, these peptides need to be synthesized in large quantities. We are requesting services for the initial synthesis of o-cresyl phosphate ester-adducted and phosphate ester adducted non-isotopically labeled (native) nonapeptides to serve as standard reference materials for the full characterization of the method in preparation for future transfer of the method to state laboratories. C.2 Project Objective - The objective of this project is to synthesize native o-cresyl phosphate ester-adducted peptides as well as native phosphate ester adducted peptide. C.3 Performance Work Study - Synthetic peptides containing an o-cresyl phosphate ester adduct will be generated using complex chemistry protocols. Additionally, the aged version of these compounds (synthetic peptides containing a phosphate ester adduct) will also be generated using similar complex chemistry protocols. A report detailing these two synthetic pathways will also be generated. C.4 Technical Requirements - • Synthesis of adducted peptides requires a chemistry protocol utilizing combinatorial chemistry reagents. The protocol for this synthesis is not publicly available and will need to be developed/optimized by the vendor. • The laboratory synthesizing these peptides must be government-sponsored, approved to work with live nerve agents, and currently using an assurity program. • Approximately 5 mg of non-isotopically labeled (native) reference peptide with serine o-cresyl phosphate ester (>90% purity as determined by HPLC-UV) will be synthesized and delivered with corresponding LC-MS and MS/MS data and brief report describing synthetic method. • Approximately 10 mg of non-isotopically labeled (native) reference peptide with a serine phosphate ester (>90% purity as determined by HPLC-UV) will be synthesized and delivered. C.5 Reporting Schedule - The contractor will report the start and completion dates for peptide synthesis as well as provide communication as necessary during the synthesis of the peptides. C.6 Special Considerations - The laboratory producing the synthetic adducted peptides must be government-sponsored and approved to work with live nerve agents. Additionally, the laboratory must have a current assurity program in place. C.7 Government Furnished Property - None Deliverables - Deliverable 1 - Approximately 5 mg of 13C-isotopically labeled reference peptide with serine o-cresyl phosphate ester (>90% purity as determined by HPLC-UV) will be synthesized and delivered; all carbon atoms in alanine will be 13C labeled, with corresponding LC-MS and MS/MS data and brief report describing synthetic method. The o-cresyl phosphate ester-adducted non-isotopically labeled (native) peptide, 5 mg; will be due one year from start date. The peptide will be sent in powered form. Deliverable 2 - Approximately 10 mg of 13C-isotopically labeled reference peptide with a serine phosphate ester (>90% purity as determined by HPLC-UV) will be synthesized and delivered; all carbon atoms in alanine will be 13C labeled. The o-cresyl phosphate ester-adducted non-isotopically labeled (native) peptide, 10 mg; will be due one year from the start date. The peptide will be sent in powdered form Performance Requirement Summaries In general, the deliverables completed by the Contractor will be evaluated in terms of how well the requirements of the contract are satisfied. The COR or COTR will inspect 100% of deliverables to ensure there is a match between actual and expected performance. If there are discrepancies, the Contract Discrepancy Report (Enclosure 1 below) will be used to communicate these performance concerns to the Contractor, and follow through to ensure performance gaps are closed. The Contracting Officer will be kept abreast of the Inspection findings and means to resolve identified performance concerns. Note: Periodic performance feedback given to the Contractor by the COR or COTR conducting inspection may be of great benefit to the Contractor by providing timely and insightful feedback about any "mid-course corrections" the Contractor may need to make to achieve the contract requirements. In addition, the information obtained from such incremental surveillance activities will form the basis for the COR completing the Performance Criteria and Their Ratings form (Enclosure 2 below). The actual Inspection conducted by the COR or COTR includes using Performance Requirement Summary (PRS). See attachment 1: Task/Deliverable Performance Standard/ Indicator Acceptable Quality Level(s) Surveillance Method Incentives o-cresyl phosphate ester-adducted non-isotopically labeled (native) peptide, 5 mg Timeliness Due 1 year from the project start date Acceptance of the delivery of Peptides Positive report regarding performance timeliness and completion of task. Quality Peptides should be shipped as powder. 0-cresyl phosphate ester-adducted 13C- isotopically labeled peptide, 10 mg: Timeliness Due 1 year from the project start date Acceptance of the delivery of Peptides Positive report regarding performance timeliness and completion of task. Quality Peptides should be shipped as powder A brief report of the synthetic pathways as described in C.3 Timeliness Due at the end of the requirement 12 months after the award Email receipt of the brief Positive report regarding performance timeliness and completion of task. It appears that TNO is the sole provider of the service for this requirement. No Request for Quote (RFQ) will be issued based upon this Notice of Intent. This advertisement ends in 3 days accordance with FAR 5.203 (A) (1). Small Businesses and any other interested companies are welcome to submit their credentials and capabilities in regards to fulfilling this requirement via e-mail at gqq4@cdc.gov. Include reference number (2012-43696). Send responses by Friday June 1, 2012.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/2012-43696/listing.html)
- Record
- SN02761777-W 20120601/120531000326-f1a593ae07abcc15039bf488bdfc445d (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |